Home Covid19 Global Covid 19 Vaccine Confusion

As several vaccines are rolled out across the world, questions already resolved in the lab are cropping up once again, as governments face the challenges of delivering the jabs to millions of people.

– Time between doses? –

All three Covid-19 vaccines authorised for use in Europe and the United States are delivered in the form of two doses.

Both mRNA vaccines, manufactured by Pfizer/BioNTech and Moderna, were administered as shots three to four weeks apart in clinical trials, which showed above 90-percent efficacy against Covid-19.

But faced with a shortage of supply and public pressure to vaccinate the maximum number of people, certain countries such as Britain and Denmark have already lengthened the gap between two doses, to six or even 12 weeks.

These delays have divided disease experts.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both advised against delaying second doses, since there is no evidence from trials that the vaccines retain their efficacy if administered so far apart.

There is also concern that longer gaps between doses could provide the ideal environment for the virus to mutate further.

With AstraZeneca’s vaccine, which uses different technology to the others to bestow immunity, there may be room for longer dosage gaps.

The EMA, for example, has authorised doses to be given between four and 12 weeks apart, since those timeframes were studied in clinical trials.

A study published this week by AstraZeneca and co-developers at Oxford University found that the vaccine was most effective (82 percent) when doses were given 12 weeks apart.

Jean-Daniel Lelievre, a disease expert from France’s public health authority, said that it was “absolutely possible” that mRNA vaccines would still be effective if delivered over a similar timeframe.

– Can vaccines be mixed? –

Russia’s Sputnik V vaccine was shown in trial results released this week to be more than 91-percent effective versus Covid-19.

This is significantly more effective than AstraZeneca’s, and involves delivering a different type of virus in the second dose.

Researchers said this method “may help create a more powerful immune response (compared with using the same vector twice)”.

So could different vaccines be used in the same patient to bestow immunity?

A trial looking at precisely that is already under way in Britain, involving more than 800 volunteers aged over 50.

One group will receive the Pfizer/BioNTech vaccine followed by AstraZeneca’s. Another will be given the inverse, then results will be compared with individuals who received two doses of a single vaccine.

This approach, known as “heterologous boosting” has shown to work in the past.

“Researchers developing some other vaccines ‒- like a better TB vaccine ‒- are looking into heterologous boosting to enhance immunity,” said Peter English, a British public health expert.

“And heterologous boosting is sometimes used in hepatitis B for people who don’t respond well to standard regimes.”

– A single dose? –

Two recent US studies suggest that a single vaccine dose may work in individuals who have already recovered from Covid-19.

One paper said that immunity in individuals who had had Covid-19 and then received a single vaccine dose “is equal to or even exceeds” that of people who have not had Covid-19 but received two vaccine doses.

Eleanor Riley, a professor at the University of Edinburgh, said the research was promising.

“However, incorporating this into a mass vaccination programme may be logistically complex and it may be safer, overall, to ensure that everyone gets two doses,” she said.

The Russian researchers behind Sputnik V said they are conducting trials on a single-dose vaccine regimen.

And there may soon be another vaccine on the table.

Developed by Johnson & Johnson, it has yet to receive emergency use authorisation from the FDA but only requires a single dose.

You may also like


Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.